Related references
Note: Only part of the references are listed.In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
Benjamin Miller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains
Carlos Juan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Activity of a New Cephalosporin, CXA-101 (FR264205), against β-Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
Yigong Ge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus β-lactamase-producing Enterobacteriaceae
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates
David M. Livermore et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Jean-Louis Vincent et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008
Victor D. Rosenthal et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2008)
In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models
W. A. Craig et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa
Shinobu Takeda et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo
Johan W. Mouton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa
Shinobu Takeda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid
WA Craig
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2003)
Animal model pharmacokinetics and pharmacodynamics: a critical review
D Andes et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Share Paper
